{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:18:27Z","timestamp":1769044707017,"version":"3.49.0"},"reference-count":22,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2014]]},"DOI":"10.1248\/bpb.b13-01006","type":"journal-article","created":{"date-parts":[[2014,3,31]],"date-time":"2014-03-31T23:20:19Z","timestamp":1396308019000},"page":"671-678","source":"Crossref","is-referenced-by-count":10,"title":["Novel Submicronized Rebamipide Liquid with Moderate Viscosity: Significant Effects on Oral Mucositis in Animal Models"],"prefix":"10.1248","volume":"37","author":[{"given":"Takako","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Pharmacokinetics and Biopharmaceutics, Subdivision of Biopharmaceutical Sciences, \u2028Institute of Health Biosciences, The University of Tokushima"},{"name":"Third Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutomo","family":"Sako","sequence":"additional","affiliation":[{"name":"Formulation Research Institute, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takakuni","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Biopharmaceutics, Subdivision of Biopharmaceutical Sciences, \u2028Institute of Health Biosciences, The University of Tokushima"},{"name":"Formulation Research Institute, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Uematsu","sequence":"additional","affiliation":[{"name":"Third Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Third Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Biopharmaceutics, Subdivision of Biopharmaceutical Sciences, \u2028Institute of Health Biosciences, The University of Tokushima"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Keeffe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE. Update clinical practice guidelines for the prevention and treatment of mucositis. <i>Cancer<\/i>, 109, 820\u2013831 (2007).","DOI":"10.1002\/cncr.22484"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients with cancer. <i>Dent. Clin. North Am.<\/i>, 52, 61\u201377, viii (2008).","DOI":"10.1016\/j.cden.2007.10.002"},{"key":"3","unstructured":"3) Uchida M, Tabusa F, Komatsu M, Morita S, Kanbe T, Nakagawa K. Studies on 2(1<i>H<\/i>)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-Chlorobenzoylamino)-3-[2(1<i>H<\/i>)\u2013quinolinon-4-yl] propionic acid and related compounds. <i>Chem. Pharm. Bull.<\/i>, 33, 3775\u20133786 (1985)."},{"key":"4","unstructured":"4) Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. <i>Eur. J. Pharmacol.<\/i>, 142, 23\u201329 (1987)."},{"key":"5","unstructured":"5) Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. <i>Dig. Dis. Sci.<\/i>, 38, 1441\u20131449 (1993)."},{"key":"6","unstructured":"6) Yoshikawa T, Naito Y, Nakamura S, Nishimura S, Kaneko T, Iinuma S, Takahashi S, Kondo M, Yamasaki K. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indometacin in rats. <i>Arzneimittelforschung<\/i>, 43, 1327\u20131330 (1993)."},{"key":"7","unstructured":"7) Sakurai K, Sasabe H, Koga T, Konishi T. Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. <i>Free Radic. Res.<\/i>, 38, 487\u2013494 (2004)."},{"key":"8","unstructured":"8) Kobayashi T, Zinchuk VS, Garcia del Saz E, Jiang F, Yamasaki Y, Kataoka S, Okada T, Tsunawaki S, Seguchi H. Suppressive effect of rebamipide, an antiulcer agent, against activation of human neutrophils exposed to formyl-methionyl-leucyl-phenylalanine. <i>Histol. Histopathol.<\/i>, 15, 1067\u20131076 (2000)."},{"key":"9","unstructured":"9) Nagano C, Azuma A, Ishiyama H, Sekiguchi K, Imagawa K, Kikuchi M. Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. <i>J. Pharmacol. Exp. Ther.<\/i>, 297, 388\u2013394 (2001)."},{"key":"10","unstructured":"10) Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M. Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. <i>Dig. Dis. Sci.<\/i>, 43 (Suppl.), 160S\u2013166S (1998)."},{"key":"11","unstructured":"11) Choe JY, Park KY, Lee SJ, Park SH, Kim SK. Rebamipide inhibits tumor necrosis factor-\u03b1-induced interleukin-8 expression by suppressing the NF-\u03baB signal pathway in human umbilical vein endothelial cells. <i>Inflamm. Res.<\/i>, 59, 1019\u20131026 (2010)."},{"key":"12","unstructured":"12) Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. <i>Dig. Dis. Sci.<\/i>, 43 (Suppl.), 5S\u201313S (1998)."},{"key":"13","unstructured":"13) Akamatsu T, Nakamura N, Furuya N, Shimizu T, Gotou A, Kiyosawa K, Katsuyama T, Osumi T, Hirao Y, Miyamoto G. Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers. <i>Dig. Dis. Sci.<\/i>, 47, 1399\u20131404 (2002)."},{"key":"14","unstructured":"14) Shioya Y, Kashiyama E, Okada K, Kusumoto N, Abe Y. Metabolic fate of the anti-ulcer agent, (\u00b1)-2-(4-chlorobenzoylamino)-3-[2(1<i>H<\/i>)-quinolinon-4-yl]propionic acid (OPC-12759): Absorption, distribution, and excretion in rats and dogs. <i>Iyakuhin Kenkyu<\/i>, 20, 522\u2013533 (1989)."},{"key":"15","unstructured":"15) Kawata K, Hanawa T, Hanawa K, Takamura T, Suzuki M, Nakajima S, Ito A, Unezaki S, Takahashi G, Sakayori S, Matsuzaki Z, Okamoto Y. Investigation of the effect of the rebamipide mouthwash on the crisis of the stomatitis induced by the cancer chemotherapy and\/or radiotherapy. <i>Journal of New Remedies &amp; Clinics<\/i>, 50, 273\u2013280 (2001)."},{"key":"16","unstructured":"16) Yasuda T, Chiba H, Satomi T, Matsuo A, Kaneko T, Chikazu D, Miyamatsu H. Preventive effect of rebamipide gargle on chemoradiotherapy-induced oral mucositis in patients with oral cancer: a pilot study. <i>J. Oral Maxillofac. Res.<\/i>, 2, 1\u20138 (2011)."},{"key":"17","unstructured":"17) Tosaka C, Tajima H, Inoue T, Moya M, Kobayashi M, Miura K, Tada Y, Masubuchi T, Hushimi C, Kamata S. Investigation of how to prevent mucositis induced by chemoradiotherapy. <i>Gan To Kagaku Ryoho<\/i>, 38, 1647\u20131651 (2011)."},{"key":"18","unstructured":"18) Matsuda T, Hiraoka S, Tomohira Y, Ishikawa S. Aqueous ophthalmic suspension of crystalline rebamipide. Japan. Patent 4934587 (2012)."},{"key":"19","unstructured":"19) Rebamipide Tablets. Official Monographs. 1337, <i>Japanese Pharmacopoeia<\/i><i>. 16th Edition (JP XVI)<\/i> (2011)."},{"key":"20","unstructured":"20) Hasegawa S, Sekino H, Matsuoka O, Saito K, Sekino H, Morikawa A, Uchida K, Koike M, Azuma J. Bioequivalence of rebamipide granules and tablets in healthy adult male volunteers. <i>Clin. Drug Investig.<\/i>, 23, 771\u2013779 (2003)."},{"key":"21","unstructured":"21) Nakashima T, Uematsu N, Shibamori M, Sakurai K, Ishida T. Establishment of an X-ray irradiation-induced glossitis model in rats: biphasic elevation of proinflammatory cytokines and chemokines. <i>J. Pharmacol. Exp. Ther.<\/i>, 347, 660\u2013668 (2013)."},{"key":"22","unstructured":"22) Sonis ST. Oral mucositis in cancer therapy. <i>J. Support. Oncol.<\/i>, 2 (Suppl. 3), 3\u20138 (2004)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/37\/4\/37_b13-01006\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T05:50:40Z","timestamp":1615873840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/37\/4\/37_b13-01006\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b13-01006","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}